Erratum: Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus (Lupus (2015) 24 (720-729) DOI: 10.1177/0961203314563818);Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

Lupus

Volumn 24, Issue 7, 2015, Pages 720-729

  Pego Reigosa, José M ^a   Rua Figueroa I ^b   Lopez Longo F J ^c   Galindo Izquierdo, M ^d   Calvo Alen J ^e   Olive Marques A ^f   Del Campo, V ^a   Garcia Yebenes M J ^g   Loza Santamaria E ^g   Blanco, R ^h   Melero Gonzalez R ^a   Vela Casasempere, P ⁱ   Oton Sanchez T ^j   Tomero Muriel, E ^k   Uriarte Isacelaya, E ^l   Fito Manteca, M C ^m   Freire Gonzalez M ⁿ   Narvaez J ^o   Fernandez Nebro A ^p   Zea Mendoza, A ^q   Carlos Rosas, J ^g,r   more..

^a Instituto de Investigación Biomédica de Vigo   (Spain)

^b Doctor Negrín University Hospital of Gran Canaria Las Palmas GC   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL SIERRALLANA   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g UNIDAD DE INVESTIGACIÓN   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j University Hospital of Torrejon   (Spain)

^k HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^l HOSPITAL DONOSTIA   (Spain)

^m Universidad Pública de Navarra   (Spain)

ⁿ HOSPITAL JUAN CANALEJO   (Spain)

^o HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^p HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^q HOSPITAL RAMÓN Y CAJAL   (Spain)

^r Marina Baixa Hospital   (Spain)

more..

Author keywords

disease activity; Systemic lupus erythematosus; treatment

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTINUCLEAR ANTIBODY;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BIOLOGICAL THERAPY; CLINICAL EVALUATION; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTERVENTION STUDY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK FACTOR; SLEDAI; SPAIN; SPANIARD; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VASCULITIS; CLINICAL TRIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREVALENCE; REGISTER; STATISTICAL MODEL;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIMALARIALS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; SPAIN;

EID: 84930831391     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315592751     Document Type: Erratum

References (48)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 ; 41: 778-799
2. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis Rheum. 2007 ; 56: 2092-2094
3. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010 ; 39: 257-268
4. Collantes E, Zarco P, Muñoz E, et al. Disease pattern of spondyloarthropathies in Spain: Description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford). 2007 ; 46: 1309-1315
5. Guañabens N, Garrido J, Gobbo M, et al. Prevalence of Paget's disease of bone in Spain. Bone. 2008 ; 43: 1006-1009
6. Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, et al. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: Data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis. 2012 ; 71: 382-385
7. Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, et al. National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: Objectives and methodology [article in English, Spanish]. Reumatol Clin. 2014 ; 10: 17-24
8. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
10. Gladman DD, Ibáñez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 ; 29: 288-291
11. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 ; 353: 2550-2558
12. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004.Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005 ; 44: 902-906
13. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
14. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 809-813
15. Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol. 2006 ; 24 (Suppl 43): S99 - S104
16. Katz JD, Senecal JL, Rivest C, Goulet JR, Rothfield N. A simple severity of disease index for systemic lupus erythematosus. Lupus. 1993 ; 2: 119-123
17. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine. 1993 ; 72: 113-124
18. Font J, Cervera R, Ramos-Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: Analysis of 600 patients from a single center. Semin Arthritis Rheum. 2004 ; 33: 217-230
19. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL Multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus. Ethnic and disease heterogeneity among "Hispanics". Medicine. 2004 ; 83: 1-17
20. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002 ; 46: 436-444
21. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus - a 5-yr prospective study. Rheumatology (Oxford). 2004 ; 43: 1039-1044
22. Toloza SM, Roseman JM, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum. 2004 ; 50: 3177-3186
23. Ibañez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol. 2005 ; 32: 824-827
24. Bandeira M, Buratti S, Bartoli M, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus. 2006 ; 15: 515-520
25. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012 ; 51: 491-498
26. Alarcón GS, McGwin G, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum. 2001 ; 45: 191-202
27. Hernández-Cruz B, Tapia N, Villa-Romero AR, Reyes E, Cardiel MH. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. Clin Exp Rheumatol. 2001 ; 19: 395-401
28. Rahman P, Gladman DD, Urowitz MB, Hallet D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001 ; 10: 93-96
29. Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis. 2002 ; 61: 1065-1070
30. Chambers SA, Allen E, Rahman A, Isenberg DA. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009 ; 48: 673-675
31. Petri M, Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: A prospective study of the Hopkins Lupus Cohort. J Rheumatol. 1992 ; 19: 1559-1565
32. Thorburn CM, Ward M. Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. Arthritis Rheum. 2003 ; 48: 2519-2523
33. Lee J, Dhillon N, Pope J. All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. Rheumatology (Oxford). 2013 ; 52: 905-909
34. Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus. 2003 ; 12: 672-676
35. Teh CL, Chan GYL, Lee J. Systemic lupus erythematosus in a tertiary, east Malaysian hospital: Admission, readmission and death. Int J Rheum Dis. 2008 ; 11: 24-29
36. Cervera R, Rúa-Figueroa I, Gil-Aguado A, et al. Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: The LUCIE Study [article in English, Spanish]. Rev Clin Esp (Barc). 2013 ; 213: 127-137
37. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000 ; 43: 1801-1808
38. Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003 ; 30: 1955-1959
39. Toloza SM, Roseman JM, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum. 2004 ; 50: 3177-3186
40. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort. Arthritis Rheum. 2012 ; 64: 4021-4028
41. Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 ; 36: 560-564
42. Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J, et al. Efficacy and safety of non-biologic immunosuppressants in the treatment of non-renal systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken). 2013 ; 65: 1775-1785
43. Aviña-Zubieta JA, Esdaile JM Dubois' lupus erythematosus and related syndromes. 8 th ed. Philadelphia: Elsevier Saunders, 2013, pp. 601-608. Wallace DJ Hahn BH, ed. Philadelphia: Elsevier Saunders ; 2013: 601-608.
44. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007 ; 66: 1168-1172
45. Shinjo SK, Bonfá E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis Rheum. 2010 ; 62: 855-862
46. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006 ; 15: 577-583
47. Campar A, Farinha F, Vasconcelos C. Refractory disease in systemic lupus erythematosus. Autoimmun Rev. 2011 ; 10: 685-692
48. Estudio EPISER: Prevalencia e impacto de las enfermedades reumáticas en la población adulta española. Madrid: MSD, Sociedad Española de Reumatología, 2001.